Comparative Pharmacology
Head-to-head clinical analysis: RANEXA versus RANOLAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RANEXA versus RANOLAZINE.
RANEXA vs RANOLAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ranolazine, an antianginal agent, inhibits the late phase of the sodium inward current (late INa) in cardiac myocytes, reducing intracellular sodium and calcium overload, thereby improving diastolic tension and oxygen consumption.
Ranolazine inhibits the late inward sodium current (late INa) in cardiac myocytes, reducing intracellular sodium and calcium overload, thereby improving myocardial relaxation and reducing oxygen demand without affecting heart rate or blood pressure.
500 mg orally twice daily; may increase to 1000 mg twice daily based on clinical response.
500 mg orally twice daily, may increase to 1000 mg twice daily based on tolerance.
None Documented
None Documented
Clinical Note
moderateRanolazine + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Ranolazine."
Clinical Note
moderateTranexamic acid + Estrone sulfate
"Tranexamic acid may increase the thrombogenic activities of Estrone sulfate."
Clinical Note
moderateRanolazine + Prednisone
"The serum concentration of Prednisone can be increased when it is combined with Ranolazine."
Clinical Note
moderateRanolazine + Hydrocortisone
Terminal elimination half-life is approximately 7 hours (range 6–10 hours) after oral administration. In patients with renal impairment, half-life may be prolonged; no clinically significant accumulation with twice-daily dosing.
Terminal elimination half-life ~7-9 hours in healthy individuals; prolonged to 12-16 hours in mild-to-moderate hepatic impairment (Child-Pugh Class A/B).
Primarily metabolized in the liver via CYP3A4 and CYP2D6; less than 5% excreted unchanged in urine. Renal excretion accounts for approximately 75% of total clearance (metabolites and unchanged drug). Fecal excretion accounts for about 25%.
Primarily hepatic metabolism (CYP3A4, CYP2D6) with <5% excreted unchanged in urine and feces. Renal excretion accounts for ~75% of total clearance of metabolites; fecal excretion ~25%.
Category C
Category C
Anti-anginal
Anti-anginal
"The serum concentration of Hydrocortisone can be increased when it is combined with Ranolazine."